TRANSFORMED MARGINAL ZONE LYMPHOMA

Clinical trials for TRANSFORMED MARGINAL ZONE LYMPHOMA explained in plain language.

Never miss a new study

Get alerted when new TRANSFORMED MARGINAL ZONE LYMPHOMA trials appear

Sign up with your email to follow new studies for TRANSFORMED MARGINAL ZONE LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New combo therapy aims to stop aggressive lymphoma relapse

Disease control Recruiting now

This study tests whether adding a drug called golcadomide after standard CAR T-cell therapy can prevent aggressive large B-cell lymphoma from returning in patients at high risk of relapse. About 65 adults will receive golcadomide for 24 weeks starting 5 days after their CAR T-cel…

Matched conditions: TRANSFORMED MARGINAL ZONE LYMPHOMA

Phase: PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control

Last updated Jun 15, 2026 19:03 UTC

TRANSFORMED MARGINAL ZONE LYMPHOMA

Get alerted when new TRANSFORMED MARGINAL ZONE LYMPHOMA trials appear

New combo therapy aims to stop aggressive lymphoma relapse